NasdaqGM:SMMTBiotechs
Why Summit Therapeutics (SMMT) Is Down 6.3% After Wider 2025 Loss and ESOP Shelf Filing
Summit Therapeutics Inc. recently reported full-year 2025 results showing a net loss of US$1.08 billion and higher per-share losses, while also filing a US$102.02 million common stock shelf registration related to its employee stock ownership plan.
Alongside these developments, Summit highlighted a cash-rich, debt-free balance sheet supporting 15 Phase 3 trials for its cancer therapy ivonescimab, plus expanding collaborations with partners such as GSK and Revolution Medicines and an accepted...